Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Glucagon-like peptide-1 Stories

2014-04-08 15:47:41

Researchers at the University of Adelaide have discovered that a common treatment for people with type 2 diabetes could cause longer-than-normal periods of the low blood sugar reaction hypoglycemia, which may result in increased health risks to people with diabetes. The treatment is the use of the peptide GLP-1 (glucagon-like peptide 1) in combination with insulin, which is now used throughout the world as a standard therapy for patients with type 2 diabetes. A team of researchers at...

2014-02-05 08:29:34

FREMONT, Calif., Feb. 5, 2014 /PRNewswire/ -- Zosano Pharma, Inc. (Zosano) announced today that it has entered into an agreement with Novo Nordisk A/S (NYSE: NVO) to develop a new transdermal presentation of semaglutide, an investigational proprietary human GLP-1 (Glucagon-Like Peptide-1) analogue, to be administered once weekly using Zosano's microneedle patch system for the treatment of type 2 diabetes. Initially, Zosano and Novo Nordisk will engage in collaborative efforts to...

2014-01-13 08:29:42

- Highlights will include first interim phase 3 data for ITCA 650, the Company's novel once or twice-yearly GLP-1 receptor agonist for type 2 diabetes. Data will show up to six months of treatment results from Intarcia's global Phase 3 clinical trial program known as FREEDOM - BOSTON, Jan. 13, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced that Chairman, President and CEO Kurt Graves will present a Company overview today at the J.P. Morgan 32nd Annual Healthcare...

2013-12-10 12:32:53

JERUSALEM, December 10, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM:ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has received allowance for a key patent from the Israeli Patent Office. The patent, entitled "Methods and Compositions for Oral Administration of Exenatide," covers oral exenatide compositions made using the company's proprietary technology....

2013-12-02 16:23:23

- Former Merck executive who co-discovered Januvia, headed Merck's global diabetes & endocrinology franchise, and led Merck's research in metabolic disorders to help guide Intarcia - BOSTON, Dec. 2, 2013 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the appointment of Nancy Thornberry to its Board of Directors. Nancy's exceptional 34-year career at Merck demonstrates the power of her insight, innovation and ability to achieve competitively superior results in the...

2013-11-26 08:28:09

Prescribers Confirm that HbA1c Reduction Remains the Key Efficacy Attribute for Antidiabetic Agents, According to a New Report from Decision Resources BURLINGTON, Mass., Nov. 26, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, among a range of current and emerging therapies, surveyed endocrinologists in the United States and Europe indicate that Eli Lilly's novel glucagon-like...

2013-11-21 11:34:57

Food transit through the small intestine affects the body's absorption of nutrients and, consequently, our health. The discovery that food transit time is regulated by a hormone indicates new ways to increase the intestinal absorption of nutrients, and thus potentially treat malnutrition. One of the tasks of the gut microbiota is to break down essential nutrients from our diet to provide a usable energy source in the colon. Researchers at the Sahlgrenska Academy, University of...

2013-11-15 08:26:53

NaZura BioHealth Presents at 2014 Obesity Society's Annual Scientific Meeting SAN DIEGO, Nov. 15, 2013 /PRNewswire/ -- NaZura BioHealth today announced clinical study results indicating that activation of taste receptors in the lower gut can amplify the release of hormones involved in satiety and glucose regulation. In an oral presentation to be made today at the Obesity Society's Annual Scientific Meeting, principal investigator Steven R. Smith, MD will describe how NaZura's proprietary Gut...

2013-10-31 10:24:53

Scientists from the Helmholtz Zentrum München (HMGU) and the Technische Universität München (TUM), together with scientists in the USA, have developed a new therapeutic approach for treatment of type 2 diabetes. A novel single molecule hormone, which acts equally on the receptors of the insulin-stimulating hormones GLP-1 and GIP, was observed to reduce weight and improve blood sugar. The results have now been published in the medical journal 'Science Translational Medicine', and include...

2013-10-16 08:28:38

DPP-IV Inhibitors Will Maintain Their Position as the Leading Drug Class Through 2022 Despite the Market Entry of Generics, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 16, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the type 2 diabetes market will nearly double over the next decade, increasing from $27 billion in sales in 2012 to $47 billion in...